Alluvi Retatrutide 20mg Injection Pen

Retatrutide is an **investigational** triple agonist (GLP-1 / GIP / glucagon receptor) still in clinical development. It is **not FDA-approved** for any use. Products sold online as “Alluvi Retatrutide 20mg Injection Pen” (or similar research pens) are not authorized pharmaceutical products for human use.

Below is neutral, factual information based on publicly available clinical data. This is **not** a product sales description and should not be used as marketing copy.

### Key Factual Details (Public Clinical Information)

– **Compound**: Retatrutide (LY3437943)

– **Developer**: Eli Lilly

– **Mechanism**: Simultaneous agonist at GLP-1, GIP, and glucagon receptors

– **Stage**: Investigational (Phase 2 data published; Phase 3 trials ongoing or planned)

– **Reported effects in trials**: Significant dose-dependent weight reduction in study participants with obesity

– **Administration in trials**: Subcutaneous injection under medical supervision

– **Status**: Not approved for sale or prescription as a finished 20 mg injection pen for consumer use

Any commercially marketed “20 mg injection pen” labeled Alluvi (or similar) is typically sold in research/gray-market channels and is **not** an approved drug product.

### Important Safety & Legal Notes

– Unapproved injectable peptides carry risks of incorrect dosing, contamination, unknown impurities, and lack of proper quality control.

– Self-administration of investigational compounds outside clinical trials is not recommended.

– Possession or distribution for human use may violate applicable laws depending on jurisdiction.

– Always consult a licensed physician for weight-management options that are legally approved and medically supervised.

### Basic FAQ (Informational Only)

**What is retatrutide?**

Retatrutide is an investigational peptide drug designed to activate three receptors involved in appetite, energy expenditure, and glucose regulation. It is still under study and is not an approved medication.

**Is the Alluvi 20 mg pen an approved product?**

No. There is no FDA-approved retatrutide injection pen available for general sale or prescription at this time.

**Has retatrutide been tested in humans?**

Yes. Published Phase 2 clinical trial results have shown substantial weight loss at various doses when administered under controlled medical conditions. Larger trials are still needed for full safety and efficacy evaluation.

**Can I legally buy and use a retatrutide pen?**

Approved versions for human use are not currently available. Research-chemical or compounded versions sold online are not authorized pharmaceuticals. Legal status varies and self-use carries significant risk.

**What are the main risks?**

Potential side effects observed in trials include gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation). Additional risks with unapproved products include unknown purity, incorrect concentration, infection from improper injection technique, and lack of medical monitoring.

**Where can I find official information?**

Refer to peer-reviewed publications, ClinicalTrials.gov, and official statements from Eli Lilly. Do not rely on vendor marketing materials.